RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
Volume: 13, Issue: 7, Pages: 1371 - 1380
Published: Jul 1, 2009
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and highly resistant to available chemotherapies. Mammalian target of rapamycin (mTOR) functions to regulate protein translation, angiogenesis and cell cycle progression in many cancers including HCC. In the present study, subcutaneous patient‐derived HCC xenografts were used to study the effects of an mTOR inhibitor, RAD001 (everolimus), on tumour growth, apoptosis and...
Paper Details
Title
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
Published Date
Jul 1, 2009
Volume
13
Issue
7
Pages
1371 - 1380
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History